

# Ramanan Laxminarayan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3061354/publications.pdf>

Version: 2024-02-01

117  
papers

18,998  
citations

57719

44  
h-index

20343

116  
g-index

119  
all docs

119  
docs citations

119  
times ranked

24230  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gender gaps in cognitive and noncognitive skills among adolescents in India. <i>Journal of Economic Behavior and Organization</i> , 2022, 193, 66-97.	1.0	7
2	The overlooked pandemic of antimicrobial resistance. <i>Lancet</i> , The, 2022, 399, 606-607.	6.3	106
3	Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 679-691.	4.6	32
4	All-cause mortality during the COVID-19 pandemic in Chennai, India: an observational study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 463-472.	4.6	28
5	Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2112410119.	3.3	18
6	Public health facility quality and child immunization outcomes in rural India: A decomposition analysis. <i>Vaccine</i> , 2022, 40, 2388-2398.	1.7	7
7	Adding to the mantra: vaccines prevent illness and death, and preserve existing antibiotics. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1108-1109.	4.6	7
8	SARS-CoV-2 testing strategies for outbreak mitigation in vaccinated populations. <i>PLoS ONE</i> , 2022, 17, e0271103.	1.1	2
9	Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–2015: an analysis of pharmaceutical sales data. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 107-115.	4.6	228
10	Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework. <i>Clinical Infectious Diseases</i> , 2021, 73, e1011-e1017.	2.9	64
11	Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine. <i>Nature Communications</i> , 2021, 12, 424.	5.8	26
12	Associations between private vaccine and antimicrobial consumption across Indian states, 2009–2017. <i>Annals of the New York Academy of Sciences</i> , 2021, 1494, 31-43.	1.8	7
13	Applying a One Health Approach in Global Health and Medicine: Enhancing Involvement of Medical Schools and Global Health Centers. <i>Annals of Global Health</i> , 2021, 87, 30.	0.8	14
14	The effect of generic market entry on antibiotic prescriptions in the United States. <i>Nature Communications</i> , 2021, 12, 2937.	5.8	6
15	Status, challenges and gaps in antimicrobial resistance surveillance around the world. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 25, 222-226.	0.9	19
16	Improving vaccination coverage and timeliness through periodic intensification of routine immunization: evidence from Mission Indradhanush. <i>Annals of the New York Academy of Sciences</i> , 2021, 1502, 110-120.	1.8	18
17	SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1665-1676.	4.6	38
18	Antimicrobial resistance in paediatric <i>Streptococcus pneumoniae</i> isolates amid global implementation of pneumococcal conjugate vaccines: a systematic review and meta-regression analysis. <i>Lancet Microbe</i> , The, 2021, 2, e450-e460.	3.4	36

#	ARTICLE	IF	CITATIONS
19	Antibiotic development – economic, regulatory and societal challenges. <i>Nature Reviews Microbiology</i> , 2020, 18, 267-274.	13.6	218
20	Epidemiology and transmission dynamics of COVID-19 in two Indian states. <i>Science</i> , 2020, 370, 691-697.	6.0	377
21	Incidence and etiology of clinically-attended, antibiotic-treated diarrhea among children under five years of age in low- and middle-income countries: Evidence from the Global Enteric Multicenter Study. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008520.	1.3	25
22	Is Gradual and Controlled Approach to Herd Protection a Valid Strategy to Curb the COVID-19 Pandemic?. <i>Indian Pediatrics</i> , 2020, 57, 505-507.	0.2	4
23	Advocacy for Increased International Efforts for Antimicrobial Stewardship Actions in Low-and Middle-Income Countries on Behalf of Alliance for the Prudent Use of Antimicrobials (APUA), Under the Auspices of the International Society of Antimicrobial Chemotherapy (ISAC). <i>Frontiers in Medicine</i> , 2020, 7, 503.	1.2	19
24	Economic and Behavioral Influencers of Vaccination and Antimicrobial Use. <i>Frontiers in Public Health</i> , 2020, 8, 614113.	1.3	33
25	Global trends in antimicrobial use in aquaculture. <i>Scientific Reports</i> , 2020, 10, 21878.	1.6	229
26	The potential global gains in health and revenue from increased taxation of tobacco, alcohol and sugar-sweetened beverages: a modelling analysis. <i>BMJ Global Health</i> , 2020, 5, e002143.	2.0	30
27	The Impact of Influenza Vaccination on Antibiotic Use in the United States, 2010–2017. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa223.	0.4	20
28	Childhood vaccinations and adult schooling attainment: Long-term evidence from India's Universal Immunization Programme. <i>Social Science and Medicine</i> , 2020, 250, 112885.	1.8	24
29	The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. <i>Lancet Infectious Diseases</i> , The, 2020, 20, e51-e60.	4.6	161
30	Childhood vaccines and antibiotic use in low- and middle-income countries. <i>Nature</i> , 2020, 581, 94-99.	13.7	85
31	India's Battle against COVID-19: Progress and Challenges. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1343-1347.	0.6	14
32	Anthropometric, cognitive, and schooling benefits of measles vaccination: Longitudinal cohort analysis in Ethiopia, India, and Vietnam. <i>Vaccine</i> , 2019, 37, 4336-4343.	1.7	30
33	Quantifying uncertainty about future antimicrobial resistance: Comparing structured expert judgment and statistical forecasting methods. <i>PLoS ONE</i> , 2019, 14, e0219190.	1.1	13
34	Global trends in antimicrobial resistance in animals in low- and middle-income countries. <i>Science</i> , 2019, 365, .	6.0	594
35	Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries. <i>The Lancet Global Health</i> , 2019, 7, e861-e871.	2.9	213
36	<i>Haemophilus influenzae</i> type b vaccination and anthropometric, cognitive, and schooling outcomes among Indian children. <i>Annals of the New York Academy of Sciences</i> , 2019, 1449, 70-82.	1.8	18

#	ARTICLE	IF	CITATIONS
37	Challenges in Antibiotic R&D Calling for a Global Strategy Considering Both Short- and Long-Term Solutions. <i>ACS Infectious Diseases</i> , 2019, 5, 1265-1268.	1.8	6
38	Tracking global trends in the effectiveness of antibiotic therapy using the Drug Resistance Index. <i>BMJ Global Health</i> , 2019, 4, e001315.	2.0	96
39	Incentivizing hospital infection control. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6221-6225.	3.3	22
40	Antibiotic resistance, stewardship, and consumption “ Authors' reply. <i>Lancet Planetary Health</i> , The, 2019, 3, e68.	5.1	0
41	Twitter to engage, educate, and advocate for global antibiotic stewardship and antimicrobial resistance. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 229-231.	4.6	18
42	Investing in antibiotics to alleviate future catastrophic outcomes: What is the value of having an effective antibiotic to mitigate pandemic influenza?. <i>Health Economics (United Kingdom)</i> , 2019, 28, 556-571.	0.8	14
43	Excessive use of medically important antimicrobials in food animals in Pakistan: a five-year surveillance survey. <i>Global Health Action</i> , 2019, 12, 1697541.	0.7	53
44	The Mortality Burden of Multidrug-resistant Pathogens in India: A Retrospective, Observational Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 563-570.	2.9	121
45	Is the efficacy of antibiotic prophylaxis for surgical procedures decreasing? Systematic review and meta-analysis of randomized control trials. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 133-141.	1.0	16
46	Simulating the impact of excise taxation for disease prevention in low-income and middle-income countries: an application to South Africa. <i>BMJ Global Health</i> , 2018, 3, e000568.	2.0	15
47	Point prevalence surveys of antimicrobial use among eight neonatal intensive care units in India: 2016. <i>International Journal of Infectious Diseases</i> , 2018, 71, 20-24.	1.5	14
48	Global forecast of antimicrobial resistance in invasive isolates of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> . <i>International Journal of Infectious Diseases</i> , 2018, 68, 50-53.	1.5	53
49	Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3463-E3470.	3.3	1,907
50	Investment in child and adolescent health and development: key messages from Disease Control Priorities, 3rd Edition. <i>Lancet</i> , The, 2018, 391, 687-699.	6.3	156
51	Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India. <i>BMJ Global Health</i> , 2018, 3, e000636.	2.0	11
52	Reply to Charra et al.: Global longitudinal assessment of 2019 changes in defined daily doses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11433-E11435.	3.3	4
53	Introduction and geographic availability of new antibiotics approved between 1999 and 2014. <i>PLoS ONE</i> , 2018, 13, e0205166.	1.1	33
54	Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. <i>Lancet Planetary Health</i> , The, 2018, 2, e398-e405.	5.1	430

#	ARTICLE	IF	CITATIONS
55	Determinants of cost of routine immunization programme in India. <i>Vaccine</i> , 2018, 36, 3836-3841.	1.7	8
56	Reply to Abat et al.: Improved policies necessary to ensure an effective future for antibiotics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8111-E8112.	3.3	4
57	Variation in cost and performance of routine immunisation service delivery in India. <i>BMJ Global Health</i> , 2018, 3, e000794.	2.0	15
58	Critical knowledge gaps and research needs related to the environmental dimensions of antibiotic resistance. <i>Environment International</i> , 2018, 117, 132-138.	4.8	281
59	Surveillance of antimicrobial consumption in animal production sectors of low- and middle-income countries: Optimizing use and addressing antimicrobial resistance. <i>PLoS Medicine</i> , 2018, 15, e1002521.	3.9	98
60	Demand- and supply-side determinants of diphtheria-pertussis-tetanus nonvaccination and dropout in rural India. <i>Vaccine</i> , 2017, 35, 1087-1093.	1.7	37
61	Correction to global antibiotic consumption data. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 476-477.	4.6	4
62	How should we respond to the emergence of plasmid-mediated colistin resistance in humans and animals?. <i>International Journal of Infectious Diseases</i> , 2017, 54, 77-84.	1.5	119
63	Reducing antimicrobial use in food animals. <i>Science</i> , 2017, 357, 1350-1352.	6.0	448
64	The quadruple burden of sepsis. <i>Cmaj</i> , 2017, 189, E1128-E1129.	0.9	6
65	Trends in Methicillin-Resistant <i>Staphylococcus aureus</i> Hospitalizations in the United States, 2010-2014. <i>Clinical Infectious Diseases</i> , 2017, 65, 1921-1923.	2.9	81
66	Clinical outcome of dual colistin- and carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infections: A single-center retrospective study of 75 cases in India. <i>American Journal of Infection Control</i> , 2017, 45, 1289-1291.	1.1	25
67	Counting the lives saved by DOTS in India: a model-based approach. <i>BMC Medicine</i> , 2017, 15, 47.	2.3	32
68	Reduced burden of childhood diarrheal diseases through increased access to water and sanitation in India: A modeling analysis. <i>Social Science and Medicine</i> , 2017, 180, 181-192.	1.8	54
69	Point Prevalence Surveys of Antimicrobial Use among Hospitalized Children in Six Hospitals in India in 2016. <i>Antibiotics</i> , 2017, 6, 19.	1.5	42
70	Use antimicrobials wisely. <i>Nature</i> , 2016, 537, 159-161.	13.7	47
71	Self-enforcing regional vaccination agreements. <i>Journal of the Royal Society Interface</i> , 2016, 13, 20150907.	1.5	16
72	Global Antibiotic Use and Resistance. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0

#	ARTICLE	IF	CITATIONS
73	A Global Antimicrobial Conservation Fund for Low- and Middle-Income Countries. <i>International Journal of Infectious Diseases</i> , 2016, 51, 70-72.	1.5	22
74	Poverty and prevalence of antimicrobial resistance in invasive isolates. <i>International Journal of Infectious Diseases</i> , 2016, 52, 59-61.	1.5	70
75	Trends in antibiotic resistance among major bacterial pathogens isolated from blood cultures tested at a large private laboratory network in India, 2008-2014. <i>International Journal of Infectious Diseases</i> , 2016, 50, 75-82.	1.5	94
76	Antimicrobial resistance—a threat to neonate survival. <i>The Lancet Global Health</i> , 2016, 4, e676-e677.	2.9	64
77	UN High-Level Meeting on antimicrobials—what do we need?. <i>Lancet, The</i> , 2016, 388, 218-220.	6.3	69
78	Cost Per DALY Averted in a Surgical Unit of a Private Hospital in India. <i>World Journal of Surgery</i> , 2016, 40, 1034-1040.	0.8	5
79	International cooperation to improve access to and sustain effectiveness of antimicrobials. <i>Lancet, The</i> , 2016, 387, 296-307.	6.3	114
80	Access to effective antimicrobials: a worldwide challenge. <i>Lancet, The</i> , 2016, 387, 168-175.	6.3	933
81	Health and economic benefits of public financing of epilepsy treatment in India: An agent-based simulation model. <i>Epilepsia</i> , 2016, 57, 464-474.	2.6	134
82	Health and economic benefits of scaling up a home-based neonatal care package in rural India: a modelling analysis. <i>Health Policy and Planning</i> , 2016, 31, 634-644.	1.0	12
83	Faropenem Consumption is Increasing in India. <i>Clinical Infectious Diseases</i> , 2016, 62, 1050.2-1052.	2.9	24
84	Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. <i>Lancet, The</i> , 2016, 387, 1672-1685.	6.3	586
85	Current costs & projected financial needs of India's Universal Immunization Programme. <i>Indian Journal of Medical Research</i> , 2016, 143, 801.	0.4	26
86	Bioeconomic analysis of child-targeted subsidies for artemisinin combination therapies: a cost-effectiveness analysis. <i>Journal of the Royal Society Interface</i> , 2015, 12, 20141356.	1.5	2
87	Are Physicians' Prescribing Decisions Sensitive to Drug Prices? Evidence from a Free-antibiotics Program. <i>Health Economics (United Kingdom)</i> , 2015, 24, 158-174.	0.8	13
88	Quantifying uncertainty in intervention effectiveness with structured expert judgement: an application to obstetric fistula. <i>BMJ Open</i> , 2015, 5, e007233-e007233.	0.8	2
89	Vaccination coverage in India: A small area estimation approach. <i>Vaccine</i> , 2015, 33, 1731-1738.	1.7	15
90	Economics of Antibiotic Growth Promoters in Livestock. <i>Annual Review of Resource Economics</i> , 2015, 7, 349-374.	1.5	31

#	ARTICLE	IF	CITATIONS
91	Influence of provider and urgent care density across different socioeconomic strata on outpatient antibiotic prescribing in the USA. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1580-1587.	1.3	38
92	Global trends in antimicrobial use in food animals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 5649-5654.	3.3	2,521
93	Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1429-1437.	4.6	270
94	The need for better evidence to evaluate the health & economic benefits of India's Rashtriya Swasthya Bima Yojana. <i>Indian Journal of Medical Research</i> , 2015, 142, 383.	0.4	13
95	Incentives for Reporting Disease Outbreaks. <i>PLoS ONE</i> , 2014, 9, e90290.	1.1	6
96	Extended-Spectrum $\beta$ -Lactamase-Producing Enterobacteriaceae Infections in Children: A Two-Center Case-Case-Control Study of Risk Factors and Outcomes in Chicago, Illinois. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2014, 3, 312-319.	0.6	29
97	Extended-Spectrum $\beta$ -Lactamase-Producing and Third-Generation Cephalosporin-Resistant Enterobacteriaceae in Children: Trends in the United States, 1999-2011. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2014, 3, 320-328.	0.6	101
98	The value of tracking antibiotic consumption. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 360-361.	4.6	10
99	Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1220-1227.	4.6	104
100	Valuing vaccines using value of statistical life measures. <i>Vaccine</i> , 2014, 32, 5065-5070.	1.7	24
101	Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim. <i>Vaccine</i> , 2014, 32, A151-A161.	1.7	35
102	Antibiotic effectiveness: Balancing conservation against innovation. <i>Science</i> , 2014, 345, 1299-1301.	6.0	146
103	Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 742-750.	4.6	1,719
104	Reassessing the value of vaccines. <i>The Lancet Global Health</i> , 2014, 2, e251-e252.	2.9	49
105	Cost-Effectiveness of Treatment and Secondary Prevention of Acute Myocardial Infarction in India: A Modeling Study. <i>Global Heart</i> , 2014, 9, 391.	0.9	19
106	Antibiotic resistance—the need for global solutions. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 1057-1098.	4.6	3,184
107	Global survey of polymyxin use: A call for international guidelines. <i>Journal of Global Antimicrobial Resistance</i> , 2013, 1, 131-134.	0.9	42
108	Seasonality and Temporal Correlation between Community Antibiotic Use and Resistance in the United States. <i>Clinical Infectious Diseases</i> , 2012, 55, 687-694.	2.9	187

#	ARTICLE	IF	CITATIONS
109	Diversify or focus? Spending to combat infectious diseases when budgets are tight. <i>Journal of Health Economics</i> , 2012, 31, 658-675.	1.3	13
110	Using Oral Vancomycin Prescriptions as a Proxy Measure for <i>Clostridium difficile</i> Infections: A Spatial and Time Series Analysis. <i>Infection Control and Hospital Epidemiology</i> , 2011, 32, 723-726.	1.0	10
111	Respiratory Fluoroquinolone Use and Influenza. <i>Infection Control and Hospital Epidemiology</i> , 2011, 32, 706-709.	1.0	25
112	India's Vaccine Deficit: Why More Than Half Of Indian Children Are Not Fully Immunized, And What Can Be Done. <i>Health Affairs</i> , 2011, 30, 1096-1103.	2.5	54
113	Synthesizing epidemiological and economic optima for control of immunizing infections. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 14366-14370.	3.3	57
114	Optimal control of epidemics in metapopulations. <i>Journal of the Royal Society Interface</i> , 2009, 6, 1135-1144.	1.5	107
115	From The Cover: Strategic interactions in multi-institutional epidemics of antibiotic resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3153-3158.	3.3	117
116	Antimicrobial resistance in developing countries. Part I: recent trends and current status. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 481-493.	4.6	624
117	Antimicrobial resistance in developing countries. Part II: strategies for containment. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 568-580.	4.6	221